E. A. Katz, M.S., Ed.D.
Abstract
Data in the literature suggests that elevated Lp(a) contributes
to coronary artery disease. This case study documents the use
of ascorbic acid, amino acids lysine and proline, an ayurvedic
herb gum guggulu, pure crystaline niacin , and guar gum in lowering
Lp(a). These natural substances were well tolerated and each
lowered Lp(a) significantly. In this study (32 months duration)
one of the above mentioned substances and/or an increase or change
in dosage was given approximately every two months to a 62 year
old female with extremely elevated familial Lp(a). Blood lipids
were drawn and results were recorded before changes were made.
At the end of 32 months Lp(a) was reduced by 8l points or 63%.
Significant re gression of coronary artery blockages was documented
by a Board Certified Cardiologist who analyzed two angiograms
performed one and half years apart, the latter performed 19 months
after the study began. It was also observed that Lp(a) decreased
directly in relation to the decrease in LDL. Research with clinical
studies is recommended to test the efficacy of the above-mentioned
nutritional substances in lowering Lp(a) and in both lessening
the risk of coronary artery disease and in regressing already
existing disease. This is especially crucial for those families
with a strong history of familial coronary artery disease and
elevated Lp(a).
Introduction
This 62 year old white female presented with an elevated cholesterol
and an extremely elevated Lp(a) one year post angioplasty. Her
family history was positive for hypercholesteremia, hypertension,
and premature death due to coronary artery disease and cardiovascular
accident. Her father died at age 43 of CAD having lived the longe
st of his four siblings. His two sisters died of CAD at ages
29 and 33, a brother died of a CVA at age 39, and the other brother
died at 41 of CAD. Patients only sibling had an angioplasty
at age 57 and coronary artery by-pass surgery at age 59. He died
one week post by-pass due to medial cystic necrosis. Out of six
cousins on her paternal side; one male died at age 50 after suffering
from CAD for 10-15 years, his sister, has had several heart attacks
since her late forties, has had a coronary artery by-pass and
is alive at age 72; another male died suddenly at age 52 of a
CVA; one female died at age 59 after having undergone two coronary
by-passes and many heart attacks since she had been 35 years old;
her surviving brother at age 69 has had two coronary by-pass
operations and several heart attacks over the past 25 years; one
male cousin, age 70, has no symptoms of CAD.
At the time of her angioplasty, patients cholesterol was elevated,
ranging from 275-296, LDL was high and her ordinarily high HDL
had fallen. At one point the ratio between her total cholesterol
and her HDL had risen to 8. She had been put on three separate
trials of lovastatin; however, each time she had to cease taking
the medication due to severe intolerance. After consulting a
lipid specialist in a large teaching hospital, she was put on
a trial of cholestyrimine. This regime lowered the total cholesterol
and LDL and the HDL increased to its more usual higher level however,
the triglycerides increased. The ratio between her total cholesterol
and HDL had improved.
Documentation
The following report documents the history of patients regime
following the discovery of extremely elevated Lp(a). Thirteen
months post angioplasty the patient was referred to a lipid specialist
who was eager to help better manage her lipids and to further
investigate the nature of the patients problem. A thorough
physical examination was performed including an examination of
the skin and the eyes for evidence of cholesterol. There was
no surface evidence; however the physician discovered the beginning
signs of cholesterol deposits in the left eye. Even though
pterygia is not associated with lipids, it is interesting to note
that the patient had noticed yellowing (pterygia) in the left
eye approximately twenty years earlier. The right eye had been
clear until the time of the angioplasty and the increase in her
lipids at which time pterygia appeared in her right eye. The
physician had also done a thorough lipid study. The results are
as follows; Total cholesterol 185 mg/dl; LDL cholesterol 94 mg/dl;
HDL cholesterol 59 mg/dl; triglyc-erides 166 mg/dl; Apolipoprotein
B 91 mg/dl; Lp(a) 128 mg/dl. The Lp(a) was well above the "less
than 20 mg/dl" recommended by the testing laboratory. The only
lipid medication the patient was taking at that time was cholestyrimine.
The patient decided to research natural substances advocated by
some physicians and scientists to lower cholesterol in the hopes
of discovering a mechanism to lower Lp(a). She had been on 1
gram of niacin for over twenty years, had been a long distance
runner (including having run a marathon at age 59), and practiced
stress reduction techniques twice daily for the same length of
time. She had been on a very low fat, low cholesterol diet as
prescribed by the Pritikin Longevity Center where she had been
a participant many times.
For the most part on the low fat, low cholesterol diet, her cholesterol
remained between 200 and 240 with the average approximately 220.
Before changing her lifestyle to this extent, her cholesterol
had been 299. Her lipid specialist neither approved nor disapproved
of the experimental regime, but agreed to monitor her blood chemistry
including her lipids and liver function.
Research
Since there were no known medicines to lower Lp(a) other than
niacin and estrogen (and perhaps Tamoxifen), and it is well known
that elevated Lp(a) is a major risk for heart attacks and strokes,1
the patient decided to research substances which would lower
Lp(a). She had come across the newsletter, Health and Healing,
by Julian Whitaker earlier and was struck by the information on
reduction of cholesterol by gugulipid, a standardized extract
of the Commiphora muklul plant. According to the article, with
200 mg four times a day, "One can expect a drop in total cholesterol
levels of approximately 24%, an increase of HDL cholesterol of
16%, and a decrease in triglycerides of 23%".2 According to Murray,
Gugulipid is an effective lipid-lowering agent.3 Safety studies
with rats, rabbits, and monkeys have demonstrated that gugulipid
is nontoxic.3 Studies have shown that gugulipid prevents the
formation of other sclerosis and aids in the regression of pre-existing
atherosclerotic plaques. This extract also appears to prevent
heart damage by free radicals as well as to improve the metabolism
of the heart. Gugulipid has a mild effect in inhibiting platelets
from aggregating.1,3 Several clinical studies have confirmed that
gugulipid has an ability to lower both cholesterol and triglyceride
levels.1,3 Typically, cholesterol levels will drop l4-27% in
a four to twelve week period and triglyceride levels will drop
22-30%.3 Paulings concept of orthomolecular medicine, which seeks
nutritional solutions to diseases based on taking in the right
[ortho] molecules in the right amounts and eliminating the wrong
ones, is highly applicable to preventing or alleviating cardiovascular
problems.4
Methodology
The procedure was to introduce a new substance after the results
of the previous test, that is, approximately every two months.
One hour aerobic exercise six to seven days per week, twice daily
stress reduction practice (20 minutes each), remained constant
and had been practiced for approximately 20 years prior to this
study. A low fat diet remained stable; however, it became more
stringent almost 100% vegetarian. Egg whites and non-fat dairy
products were consumed in moderation. Patient tried to maintain
a 10% fat intake daily and only on occasion 5-10 mgs of cholesterol.
The patient continued her long term use of vitamins B, C, E, calcium
and anti-oxidants. Hormone replacement therapy commenced six
months prior to the initial exam and onset of the study and remained
constant. Estrace l mg. and Provera 2.5mg daily were prescribed.
Any substance introduced with the intention to specifically alter
lipids was tried one substance per blood drawing interval as noted
in Table 1 (p 176). Table 1 covers 32 months, from April 4,1993
until December 22,1995. Included are the different substances
ingested and the results of lipid blood chemistry taken at approximately
two month intervals.
Analysis
Because of the above reports, patient decided to explore gugulipid
as the first Lp(a) lowering agent. For the purpose of this
paper, gugulipid will be described by the content of the substance
used, guggulsterones referring to 25 mg per dose except for the
first introduction which was a form of gugulipid which combines
other ingredients with gum guggulu. After the first blood test,
patient introduced gugulipid 250 mg 3 times per day. There was
a rise in total cholesterol, a rise in HDL and LDL, a lowering
of triglycerides and a significant lowering of Lp(a) of 33 points
or approximately 28%.
The first large drop in total cholesterol and a second drop in
Lp(a) occurred between 5/3/93 and 6/18/93 with the introduction
of guggulsterones 25 mg. 4 times per day and niacin 1 gram per
day. Total cholesterol dropped 46 points, triglycerides dropped
82 points, HDL increased four points, LDL decreased 47 points
and Lp(a) decreased 33 points. With the introduction of lysine
and garlic, values of 9/1/93 reveal another impressive drop of
25 points in total cholesterol. Other values improved and there
was another drop in Lp(a) of 16 points resulting in a total drop
in Lp(a) of 84 points since 4/4/93. Lysine has been shown to
act as an anti-adhesive material to the binding of lipoprotein(a)
particles inside the blood vessel wall and can thus reverse atherosclerotic
deposits.1
With the introduction of 6 g of vitamin C, (ascorbic acid), bloods
values of 12/8/93 are similar across the board except for a 10
point increase in total cholesterol to 153 and an 18 point increase
in Lp(a). According to Rath, vitamin C along with niacin can
lower blood levels of Lp(a).1 Niedzweiki states that clinical
studies have shown that vitamin C can lower elevated LDL levels
and increase HDL. Studies at LPI with guinea pigs suggest that
large dosages of vitamin C can prevent pathologic changes in blood
vessel walls generated by atherosclerotic diets.5
In the paper A Unified Theory of Human Cardiovascular Disease,
Rath and Pauling state that "Ascorbic deficiency is the precondition
and common denominator of human CVD."6 They continue, "The metabolic
level is characterized by the close connection of ascorbate with
metabolic regulatory systems that determine the risk profile of
CVD in clinical cardiology today. The most frequent mechanism
is the deposition of lipoproteins, particularly lipoprotein(a)
[Lp(a)], in the vascular wall. With sustained ascorbate uptake,these
defense mechanisms overshoot and lead to the development of CVD."6
Two additions are reflected in the blood values of 2/16/94, i.e.,
an increase of lysine to 4 g and an increase of vitamin C to 8
g. The values reflect an overall decrease in lipids across the
board including a 9 point decrease in HDL. Total cholesterol
decreased 7 points to 146 and Lp(a) decreased 24 points to 38
, 90 points lower than the first Lp(a) reading 10 months prior.
At this time, another lab was introduced to measure Lp(a) because
the physician monitoring the patient believed it to be more accurate.
For the purpose of this paper the readings of the first lab will
be considered primary since it is constant; however readings from
the additional lab will be included. For the most part, even
though the numbers are different, results from both labs move
in the same direction.
On 4/22/94, all values increase slightly including HDL ; however,
there was a drop in Lp(a), 3 and 4 points respectively from each
lab. This change was necessitated by the discontinuance of the
manufacturing of Lonicin, the specific formula comprised of pure
crystalized niacin, guar gum, and vitamin C. The values drawn
on 5/23/94 represent a change in the brand of niacin to a time
release formula. The results of blood values drawn reveal an increase
in all values and a decrease in HDL with a 27 point increase in
Lp(a). The values drawn on 7/22/94 represent the addition of 1
tablespoon of Guar Aid (guar gum fiber and vitamin C), and a change
to pure crystallized niacin,7 with values moving both up and down
however only slightly.
Blood values drawn on 9/7/94 represent an increase in Guar Aid
to 3 tbsp. Values dropped significantly across the board; 27 points
in total cholesterol, 30 in triglycerides, an increase of 20 points
in HDL, a decrease of 39 in LDL and an increase of 7 points in
Lp(a) from the first lab and a decrease of 15 points from the
second lab. October 31,1994 represents an increase in pure crystalized
niacin to 3.2 grams and an introduction to proline 2.7 grams.8
Values improved across the board with a lowering of total cholesterol
46 points to 113, lowering of triglycerides 21 points to 34, HDL
lowered to 64, LDL lowered 26 points to 42, and Lp(a) lowered
23 points to 30 and 23 points to 47 respectively. A new therapeutic
approach is the use of L-lysine and L-proline. These natural amino
acids provide a teflon layer which detaches lipo-protein(a) and
other risk factors from their deposits inside the blood vessel
wall. By releasing thousands of lipoprotein(a) particles from
the blood vessel wall lysine and proline help reverse existing
cardiovascular disease.1
Values drawn on 12/28/94, represent a reduction of niacin to
l.5 grams, a reduction of Guar Aid to l l/2 tbsp, a reduction
of lysine to 3 g and a reduction of vitamin C to 7.5 g. Values
increased across the board with a 49 point reduction in cholesterol,
a 5 point reduction in HDL and a 38 and 63 point increase in Lp(a)
respectively. An angiogram had been performed 5 weeks prior to
this drawing which may have affected Lp(a).
The values on 3/31/95 represent an increase of Guar Aid to 2 tbsp.
Values were reduced across the board and there was a 3 point
increase in HDL. Lp(a) was reduced by 5 points and 3 8 points
respectively. The values of 6/16/95 utilizing the same substances
vary both upward and downward with a total cholesterol of 185,
an increase of 26 points, an increase of HDL of 3 points, a slight
increase in one lab and and decrease in the other with regard
to Lp(a).
The values of 8/9/95 represent an increase of lysine to 4 g and
blood values were reduced across the board with a lowering of
total cholesterol 11 points, an increase in HDL of 2 points, and
a decrease in Lp(a) 13 and 11 points respectively. The values
of 9/22/95 represent a change to pure guar gum, one tbsp, (a decrease
in the amount of guar gum) and values remain relatively unchanged
except for the Lp(a) which increased 16 points and 4 points, respectively.
No changes in substances nor amounts taken were made in the period
reflected by the blood results of 12/22/95. Cholesterol reduced
by 6 points, triglycerides by 24 points, HDL increased 3 points,
LDL decreased 4 points and Lp(a) was reduced by 16 and 10 points
in the results of the respective labs.The most outstanding change
in blood values in the 32 months followed was the dramatic decrease
in Lp(a), 81 points from the first to the last drawing, a total
of 63%.
Results
Significant lowering in all blood lipid values including Lp(a)
and excluding HDL is evident. Examination of the eyes by the
lipid specialist 11/4 years after the initial exam no longer shows
evidence of cholesterol deposits in the left eye. Pterygia in
both eyes has diminished. Thallium stress test has improved by
1 1/2 minutes in duration totaling 16 1/2 minutes on the standard
Bruce protocol and reveal normal profusion. Cardiac catheterization
on 11/23/94 revealed a reduction of stenosis of the mid RCA from
75% to 40% since prior catheterization of April, 1993. Other
lesions approximately 50% and less noted in 1993 were not noted
in 1994. Analysis of the two catheterization by a Board Certified
Cardiologist verified the significant reduction of coronary artery
disease.
Conclusions
1) This individual did indeed reduce the severity of her CAD by
reducing the blockages in her arteries.
2) The substances, vitamin C, pure crystalized niacin, guar
gum, two specific amino acids, lysine and proline, and an herb
composed of guggulsterones contributed to the significant reduction
of cholesterol and Lp(a) and improved lipid profile thus leading
to the regression of blockages in her coronary arteries.
3) Lp(a) can be reduced significantly with vitamin C, pure crystalized
niacin, guar gum, lysine, proline and guggulsterones.
4) Reversal of coronary artery disease can be accomplished by
a reduction of Lp(a) through the use of a combination of vitamin
C, pure crystalized niacin, lysine, proline, guggulsterones
and guar gum.
5) Reduction of coronary artery disease can be accomplished by
nutritional substances in addition to a strict regimen of diet,
exercise and the practice of stress reduction techniques.
Recommendations
It is important to do clinical studies with control groups to
research the effect of the combination of ascorbic acid, guggulsterones,
lysine, proline, pure
crystallized niacin and guar gum in
reducing elevated Lp(a) and coronary
artery disease. This is especially crucial for those families
who have a strong history of early CAD and high Lp(a).
Since there is no prescription medicine readily available to lower
Lp(a) and it is known that elevated Lp(a) is a significant factor
in developing CAD,1,6 the above-mentioned nutritional substances
can be crucial in improving the health and increasing the longevity
of individuals and families with elevated Lp(a).
References